Fundraising Fox
Mineralys Therapeutics
NASDAQ: MLYSRadnor, US · Founded 2019 · Delaware corporation · 10 known investors
Find your way into Mineralys Therapeutics
Sign up to see every warm intro you have to Mineralys Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Mineralys Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Mineralys Therapeutics is a clinical-stage pharmaceutical company developing lorundrostat, a treatment targeting dysregulated aldosterone. It focuses on cardio-renal-metabolic diseases, including hypertension and chronic kidney disease.
Founders & leadership
Board
Investors · 10
How we know: a partner's Signal profile · Not right? Tell us
How we know: HBM Healthcare Investments's portfolio page · Not right? Tell us
How we know: HBM Partners's portfolio page · Not right? Tell us
How we know: Samsara BioCapital's portfolio page · the S-1 prospectus · board seat on SEC Form D · Not right? Tell us
How we know: SR One Capital Management's portfolio page · Not right? Tell us
How we know: Ysios Capital's portfolio page · a partner's Signal profile · the VCSheet dataset · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
How we know: the S-1 prospectus · board seat on SEC Form D · Not right? Tell us
How we know: the S-1 prospectus · board seat on SEC Form D · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$118M disclosed across 1 of 3 rounds · 1900–2022
▶$118MraisedJun 2022 · 23 investors · PharmaceuticalsRule 506(b)
- Brian Taylor SlingsbyDirector
- Olivier LitzkaDirector
- Derek DiRoccoDirector
- Adam LevyExecutive Officer
- Jon CongletonExecutive Officer, Director
- Srinivas AkkarajuDirector
- Alexander AsamDirector
- Takeshi TakahashiDirector
- Offering amount
- $118M
- Amount sold
- $118M
- First sale
- Jun 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Founder mafia
2 people who came through Mineralys Therapeutics went on to found or lead other companies.
Related companies · 5
Companies working in the same space as Mineralys Therapeutics.
Frequently asked questions
- What does Mineralys Therapeutics do?
- Mineralys Therapeutics is a clinical-stage pharmaceutical company developing lorundrostat, a treatment targeting dysregulated aldosterone. It focuses on cardio-renal-metabolic diseases, including hypertension and chronic kidney disease.
- Who are Mineralys Therapeutics's investors?
- Mineralys Therapeutics's investors include Andera Partners, HBM Healthcare Investments, HBM Partners, Samsara BioCapital, SR One Capital Management, Ysios Capital, Adams Street Partners, Boulder Ventures and 2 more.
- How much funding has Mineralys Therapeutics raised?
- Mineralys Therapeutics has disclosed $118M raised across 1 of its 3 known rounds.
- Where is Mineralys Therapeutics headquartered?
- Mineralys Therapeutics is headquartered in Radnor, US.